177 related articles for article (PubMed ID: 7624956)
1. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME
Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956
[TBL] [Abstract][Full Text] [Related]
2. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
Andrew M; Brooker L; Leaker M; Paes B; Weitz J
Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
[TBL] [Abstract][Full Text] [Related]
3. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
4. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
5. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
[TBL] [Abstract][Full Text] [Related]
7. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
8. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
Wootton DM; Popel AS; Alevriadou BR
Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
[TBL] [Abstract][Full Text] [Related]
9. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
11. Absence of inhibition by lipoprotein (a) inhibition of tPA induced thrombolysis in a patient's plasma milieu.
Lu H; Bruckert J; Soria J; Li H; de Gennes JL; Legrand A; Peynet J; Soria C
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):513-6. PubMed ID: 1966796
[TBL] [Abstract][Full Text] [Related]
12. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
13. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
[TBL] [Abstract][Full Text] [Related]
14. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Downing A; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1994 Dec; 58(12):1356-60. PubMed ID: 7528949
[TBL] [Abstract][Full Text] [Related]
16. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
GuimarĂ£es AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
17. Standard and low molecular weight heparin have no effect on tissue plasminogen activator induced plasma clot lysis or fibrinogenolysis.
Weitz JI; Kuint J; Leslie B; Hirsh J
Thromb Haemost; 1991 May; 65(5):541-4. PubMed ID: 1651568
[TBL] [Abstract][Full Text] [Related]
18. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
19. A plasma clot lysis assay based on the release of fibrin degradation products: application to the diagnosis of hypofibrinolytic states.
Gaussem P; Gandrille S; Molho-Sabatier P; Capron L; Fiessinger JN; Aiach M
Thromb Haemost; 1990 Feb; 63(1):76-81. PubMed ID: 2111050
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and biophysical conditions for blood clot lysis.
Sabovic M; Blinc A
Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]